Early Intra-aortic Balloon Pump Use After Venoarterial Extracorporeal Membrane Oxygenation
Launched by BEIJING ANZHEN HOSPITAL · Mar 6, 2025
Trial Information
Current as of April 30, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how using a device called an Intra-aortic Balloon Pump (IABP) early during treatment can help patients with a serious heart condition known as cardiogenic shock. Specifically, the trial compares this approach to the usual methods used when patients are on a special life-support system called venoarterial extracorporeal membrane oxygenation (VA-ECMO). The main goal is to see if using the IABP can improve health outcomes for these patients.
To participate in this trial, individuals must be at least 18 years old, have cardiogenic shock, and have successfully received VA-ECMO. However, certain conditions, like severe issues with the heart valves or significant bleeding problems, would make someone ineligible. Participants will be randomly assigned to either receive the IABP or follow the standard treatment. This trial is not yet recruiting patients, but it aims to provide valuable information about how to improve care for people with severe heart problems.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age of ≥18
- • 2. Cardiogenic shock
- • 3. Successful implantation of VA-ECMO
- • 4. Informed consent
- Exclusion Criteria:
- • 1. Presence of moderate to severe aortic insufficiency
- • 2. Severe peripheral vascular disease
- • 3. Post-cardiotomy cardiogenic shock or bridging to cardiac procedure.
- • 4. VA-ECMO for definite non-cardiac causes
- • 5. Extracorporeal cardiopulmonary resuscitation
- • 6. Implantation of IABP or IMPELLA before VA-ECMO
- • 7. Severe bleeding
- • 8. Terminal malignancy
- • 9. Irreversible neurologic injury
- • 10. Pregnancy or lactation
About Beijing Anzhen Hospital
Beijing Anzhen Hospital is a leading medical institution in China, renowned for its expertise in cardiovascular diseases and comprehensive healthcare services. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical research and innovation, facilitating the development of new therapies and treatment protocols. With a focus on patient safety and ethical standards, Beijing Anzhen Hospital collaborates with various research entities to conduct rigorous clinical studies aimed at improving patient outcomes and enhancing the understanding of cardiovascular health. Its commitment to excellence in clinical research is underscored by a multidisciplinary team of experienced healthcare professionals and a state-of-the-art facility equipped to support a wide range of clinical investigations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Xiaotong Hou, MD, PhD
Principal Investigator
Beijing Anzhen Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported